Диссертация (1141351), страница 18
Текст из файла (страница 18)
38. – №. 4. – P. 552-562.38. Beck O. Detectability of new psychoactive substances, "legal highs", in111CEDIA, EMIT, and KIMS immunochemical screening assays for drugs of abuse / O.Beck [et al.] // Drug testing and analysis. – 2014. – V. 6. – №. 5. – P.
492-499.39. Beck O. Intoxications involving MDPV in Sweden during 2010–2014: resultsfrom the STRIDA project / O. Beck [et al.] // Clinical toxicology. – 2015. – V. 53. – №.9. – P. 865-873.40. Biliński P. Designer Drug (DD) abuse in Poland; a review of the psychoactiveand toxic properties of substances found from seizures of illegal drug products and thelegal consequences thereof. Part 1 – cannabinoids and cathinones / P. Biliński, P.Hołownia, L. Kapka-Skrzypczak, A.
Wojtyła // Annals of Agricultural andEnvironmental Medicine. – 2012. – V. 19. – №. 4. – P. 857-870.41. Bonano J. Abuse-related and abuse-limiting effects of methcathinone and thesynthetic "bath salts" cathinone analogs 26 methylenedioxypyrovalerone (MDPV),methylone and mephedrone on intracranial self-stimulation in rats / J.
Bonano [et al.] //Psychopharmacology. – 2014. – V. 231. – №. 1. – P. 199-207.42. Borek H. Hyperthermia and multiorgan failure after abuse of "bath salts"containing 3,4-methylenedioxypyrovalerone / H. Borek, C. Holstege // Annals ofemergency medicine. – 2012. – V. 60. – №. 1. – P. 103-105.43. Busardo F. Assessment of the stability of mephedrone in ante-mortem andpostmortem blood specimens / F. Busardo [et al.] // Forensic science international. – 2015.– V. 256.
– P. 28-37.44. Canada's Controlled Drugs and Substances Act, Schedule 4 [Электронныйресурс]. – Режим доступа: http://laws-lois.justice.gc.ca/eng/acts/C-38.8/ – (датаобращения: 12.02.2017).45. Casale J. The characterization of α-pyrrolidinopentiophenone / J. Casale, P.Hays // Microgram Journal – 2012. – V. 9. – P. 33-38.46. Cawrse B. Distribution of methylone in four postmortem cases / B. Cawrse [etal.] // Journal of analytical toxicology.
– 2012. – V. 36. – №. 6. – P. 434-439.47. Class C Drugs. Schedule 2 Controlled Drugs. United Kingdom Legislation[Электронныйресурс].–Режимдоступа:https://www.legislation.-gov.uk/ukpga/1971/38/schedule/2 – (дата обращения: 12.02.2017).11248. CoppolaM.3,4-methylenedioxypyrovalerone(MDPV):chemistry,pharmacology and toxicology of a new designer drug of abuse marketed online / M.Coppola, R.
Mondola // Toxicology Letters. – 2012. – V. 208. – №. 1. – P. 12-15.49. Cottencin O. New designer drugs (synthetic cannabinoids and syntheticcathinones): review of literature / O. Cottencin, B. Rolland, L. Karila // Currentpharmaceutical design. – 2014. – V. 20. – №. 25. – P. 4106-4111.50. Deluca P. MDPV report. Psychonaut Research Web Mapping Project / P.Deluca [et al.] – 2010.51. Dizikes C. Khat – Is it more coffee or cocaine? The narcotic leaf is a timehonored tradition in Africa but illegal in the US, where demand is growing // Los AnglesTimes (30.09 9). – 2009.52. Ellefsen K.
Quantificatio of methylone and metabolites in rat and humanplasma by liquid chromatography-tandem mass spectrometry / K. Ellefsen, M. Concheiro,M. Suzuki // Forensic Toxicology. – 2015. –V. 33. – №. 2. – P. 202-212.53. Ellefsen K. Synthetic cathinone pharmacokinetics, analytical methods, andtoxicological findings from human performance and postmortem cases / K. Ellefsen, M.Concheiro, M. Huestis // Drug metabolism reviews. – 2016. – V. 48.
– №. 2. – P. 237265.54. Emerson T. Methcathinone: a Russian designer amphetamine infiltrates therural midwest / T. Emerson, J. Cisek // Annals of emergency medicine. – 1993. – V. 22.– №. 12. – P. 1897-1903.55. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).European Drug Report 2014: Trends and Developments. – 2014.56. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).Report on the risk assessment of 1-(1,3-benzodioxol-5-yl)-2-(pyrrolidin-1-yl) pentan-1one (3,4-methylenedioxypyrovalerone, MDPV) in the framework of the Council Decisionon new psychoactive substances.
– 2014.57. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).EuropolJointReportonanewmethylenedioxypyrovalerone). – 2014.psychoactivesubstance:MDPV(3,4-11358. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).Europol Joint Report on a new psychoactive substance: 1-phenyl-2-(1-pyrrolidinyl)-1pentanone (α-PVP). – 2015.59. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).Synthetic cathinones drug profile [Электронный ресурс]. – Режим доступа:http://www.emcdda.europa.eu/publications/drug-profiles/ synthetic-cathinones – (датаобращения: 22.07.2016).60.
Gannon B. Reinforcing effects of abused "bath salts" constituents 3,4methylenedioxypyrovalerone and α-pyrrolidinopentiophenone and their enantiomers / B.Gannon, K. Rice, G. Collins // Behavioural pharmacology. – 2017. – V. 28. – №. 7. – P.578-581.61. Giannotti G. The Cathinones MDPV and α-PVP Elicit Different Behavioraland Molecular Effects Following Acute Exposure / G. Giannotti [et al.] // Neurotoxicityresearch. – 2017. – V. 32. – №.
4. – P. 594-602.62. Glennon R. Neurobiology of 3,4-methylenedioxypyrovalerone (MDPV) andα-pyrrolidinovalerophenone (α-PVP) / R. Glennon, R. Young // Brain research bulletin.– 2016. – V. 126. – P. 111-126.63. Glicksberg L., Kerrigan S. Stability of synthetic cathinones in urine //Journalof analytical toxicology. – 2017.
– V. 42. – №. 2. – P. 77-87.64. Glicksberg L., Rana S., Kerrigan S. Cathinone stability in authentic urinespecimens //Forensic science international. – 2018. – V. 286. – P. 54-60.65. Grapp M. Toxicological investigation of forensic cases related to the designerdrug 3,4-methylenedioxypyrovalerone (MDPV): Detection, quantification and studies onhuman metabolism by GC–MS / M. Grapp, C.
Kaufmann, M. Ebbecke // Forensic scienceinternational. – 2017. – V. 273. – P. 1-9.66. Grapp M. GC–MS analysis of the designer drug α-pyrrolidinovalerophenoneand its metabolites in urine and blood in an acute poisoning case / M. Grapp [et al.] //114Forensic science international. – 2016. – V. 259. – P. e14-e19.67. Gregg R. Behavioral pharmacology of designer cathinones: a review of thepreclinical literature / R. Gregg, S. Rawls // Life sciences.
– 2014. – V. 97. – №. 1. – P.27-30.68. Hasegawa K. Postmortem distribution of α-pyrrolidinovalerophenone and itsmetabolite in body fluids and solid tissues in a fatal poisoning case measured by LC–MS–MS with the standard addition method / K. Hasegawa [et al.] // Forensic Toxicology. –2014. – V. 32. – №. 2. – P. 225-234.69.
Johnson R. The stability of four designer drugs: MDPV, mephedrone, BZP andTFMPP in three biological matrices under various storage conditions / R. Johnson, S.Botch-Jones // Journal of analytical toxicology. – 2013. – V. 37. – №. 2. – P. 51-55.70. Karila L. Synthetic cathinones: a new public health problem / L. Karila [et al.]// Current neuropharmacology.
– 2015. – V. 13. – №. 1. – P. 12-20.71. Katselou M. α-PVP ("flakka"): a new synthetic cathinone invades the drugarena / M. Katselou [et al.] // Forensic Toxicology. – 2016. – V. 34. – №. 1. – P. 41-50.72. Kelly J. Cathinone derivatives: a review of their chemistry, pharmacology andtoxicology / J. Kelly // Drug testing and analysis. – 2011. – V. 3. – №. 7‐8. – P. 439-453.73. Khreit O. Synthesis, full chemical characterisation and development ofvalidated methods for the quantification of the components found in the evolved “legalhigh” NRG-2 / O.
Khreit [et al.] // Journal of pharmaceutical and biomedical analysis. –2012. – V. 61. – P. 122-135.74. Kolanos R. Stereoselective actions of methylenedioxypyrovalerone (MDPV)to inhibit dopamine and norepinephrine transporters and facilitate intracranial selfstimulation in rats / R. Kolanos [et al.] // ACS chemical neuroscience. – 2015. – V. 6. –№.
5. – P. 771-777.75. Lehmann S. Organ distribution of 4-MEC, MDPV, methoxetamine and αPVP: comparison of QuEChERS and SPE / S. Lehmann [et al.] // Forensic Toxicology. –2018. – P. 1-14.76. Levenson M. Antidepressants and suicidality in adults: statistical evaluation /115M. Levenson, C. Holland // Presentation at Psychopharmacologic Drugs AdvisoryCommittee. – 2006.77. Liveri K.
A fatal intoxication related to MDPV and pentedrone combined withantipsychotic and antidepressant substances in Cyprus / K. Liveri [et al.] // Forensicscience international. – 2016. – V. 265. – P. 160-165.78. Marinetti L. Analysis of synthetic cathinones commonly found in bath salts inhuman performance and postmortem toxicology: method development, drug distributionand interpretation of results / L. Marinetti, H.
Antonides // Journal of analyticaltoxicology. – 2013. – V. 37. – №. 3. – P. 135-146.79. Marusich J. Pharmacology of novel synthetic stimulants structurally related tothe "bath salts" constituent 3,4-methylenedioxypyrovalerone (MDPV) / J. Marusich [etal.] // Neuropharmacology. – 2014. – V. 87. – P. 206-213.80. Meyer M.
Studies on the metabolism of the α‐pyrrolidinophenone designerdrug methylenedioxy‐pyrovalerone (MDPV) in rat and human urine and human livermicrosomes using GC–MS and LC–high‐resolution MS and its detectability in urine byGC–MS / M. Meyer [et al.] // Journal of Mass Spectrometry. – 2010. – V. 45. – №. 12. –P. 1426-1442.81. Murray B. Death following recreational use of designer drug "bath salts"containing 3,4-methylenedioxypyrovalerone (MDPV) / B. Murray, C. Murphy, M.Beuhler // Journal of Medical Toxicology.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
